Scarica l'app Stockscreener
0.72
1.11%
0.0079
Dopo l'orario di chiusura:
.74
0.02
+2.78%
Precedente Chiudi:
$0.7121
Aprire:
$0.72
Volume 24 ore:
159.08K
Relative Volume:
0.58
Capitalizzazione di mercato:
$33.72M
Reddito:
$10.85M
Utile/perdita netta:
$-51.31M
Rapporto P/E:
-0.9769
EPS:
-0.737
Flusso di cassa netto:
$-40.15M
1 W Prestazione:
+3.00%
1M Prestazione:
-7.14%
6M Prestazione:
-58.14%
1 anno Prestazione:
-70.37%
Intervallo 1D:
$0.6701
$0.72
Intervallo di 1 settimana:
$0.6601
$0.72
Portata 52W:
$0.63
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Nome
InspireMD Inc.
Settore
Industria
Telefono
972 3 6917691
Indirizzo
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.72 | 33.72M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Maxim Group | Buy |
| 2016-01-07 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2013-11-26 | Iniziato | Oppenheimer | Outperform |
InspireMD Inc. Borsa (NSPR) Ultime notizie
InspireMD director Raymond W. Cohen to resign from board effective July 1, 2026 - TradingView
Board member Raymond Cohen to leave InspireMD (NSPR) effective July 1, 2026 - Stock Titan
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBIT forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
NSPR Q1 2026 Earnings: EPS Beat Surprises as Revenue Remains UndisclosedEPS Consistency Score - dars.gov.et
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Inc. (NSPR) Gains Momentum: Breaking Above Key SupportMarket Leader Picks - dars.gov.et
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD Inc. Azioni (NSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):